DC-6001 (DCSZ11)
Advanced Cancers
Phase 1 (Planned)Active
Key Facts
About DynamiCure
DynamiCure is a private, pre-revenue biotechnology company founded in 2018 and headquartered in Waltham, Massachusetts. The company's core focus is 'immuno-normalization,' an approach aimed at restoring immune system balance to treat cancer and autoimmune disorders. Its most advanced asset, DC-6001, consists of two anti-CD93 monoclonal antibodies, with one currently in a Phase 1 clinical trial for advanced cancers. The company is led by scientific founder Dr. Lieping Chen, a world-renowned immunologist who pioneered the PD-1/PD-L1 pathway research.
View full company profileTherapeutic Areas
Other Advanced Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| MDX2004 | Opko Health | Phase 1 |
| DC-6001 (DCBY02) | DynamiCure | Phase 1 |
| INA03 | Inatherys | Preclinical |
| IBI-110 | Innovent Biologics | Phase 2 |
| NXP900 | Nuvectis Pharma | Phase 1 |